Boost For India’s Generic Pharma Majors
Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a growing market.
biosimilars
October 2024
March 2022
January 2022
January 2021
September 2019
November 2018
India's bio-economy's quest to be the global eco-system
The Indian bioeconomy has grown around tenfold in a decade and is expected to double in the next few years.
WHO proposal to exempt biosimilar trials to trigger biotech generics boom
The proposal, once approved and adopted by member countries, could trigger a bigger interest in developing generic versions of biotech medicines in India.
Waive off clinical trials for biosimilars on WHO, UK format, says plea to Centre
Advocacy groups say move will ensure accessibility and affordability of mABs and other bio-therapeutics in the country.
Biocon’s biosimilar biz tops $4 bn in valuation
Abu Dhabi-based sovereign wealth fund ADQ has picked up 1.80% stake in Biocon Biologics for $75 million; The company already raised $255 million from global marquee investors last year.
Healthcare spending to double by 2030: Bain report
Upper-middle-income households becoming the biggest demographic in 2030 will drive healthcare services.
The toughest period is behind us: Vinita Gupta
India’s third-largest generic drugmaker Lupin is focussing on building a pipeline of specialty drugs, while cutting costs and addressing regulatory concerns.
Kiran Mazumdar-Shaw: Grit is her secret formula
Overcoming years of criticism and gender bias, Mazumdar-Shaw has proven naysayers wrong by positioning Biocon as an Indian pioneer in the lucrative biologic drugs market.
